Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | CFD | P00746 | 3/20 | 0.58 |
| ▸ | F11 | P03951 | 3/20 | 0.58 |
| ▸ | TPSB2 | P20231 | 3/20 | 0.58 |
| ▸ | PLG | P00747 | 1/20 | 0.58 |
| ▸ | PLAU | P00749 | 1/20 | 0.58 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.58 |
| ▸ | F7 | P08709 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.55 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.55 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.55 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL22289610 | 0.98 | HTR1A (0.57) | HTR1ADRD2CFDF11TPSB2 | |
| SCHEMBL1462035 | 0.88 | HTR1A (0.57) | HTR1ADRD2CFDF11TPSB2 | |
| SCHEMBL31757878 | 0.88 | HTR1A (0.57) | HTR1ADRD2CFDF11TPSB2 | |
| SCHEMBL31757965 | 0.88 | CFD (0.68) | HTR1ADRD2CFDF11TPSB2 | |
| SCHEMBL1007508 | 0.88 | CFD (0.68) | HTR1ADRD2CFDF11TPSB2 | |
| SCHEMBL68571 | 0.85 | L3MBTL1 (0.69) | HTR1ADRD2CFDF11TPSB2 | |
| SCHEMBL29291239 | 0.84 | GAA (0.54) | HTR1ADRD2CFDF11TPSB2 | |
| SCHEMBL16397532 | 0.84 | CFD (0.56) | CFDF11TPSB2PLGPLAU | |
| SCHEMBL9732671 | 0.84 | PTGER1 (0.57) | CFDF11TPSB2PLGPLAU | |
| SCHEMBL8324677 | 0.83 | L3MBTL1 (0.64) | HTR1ADRD2CFDF11TPSB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004056744-A1 | ADAMANTYL ACETAMIDES AS HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-08 | — | — | WO | claimed |
| EP-1448535-B1 | BENZAMIDE AND HETEROARYLAMIDE AS P2X7 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090247734-A1 | Chemically Derivatized CD4 and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-10-01 | — | — | US | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| WO-2007075414-A2 | CHEMICALLY DERIVATIZED CD4 AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-07-05 | — | — | WO | disclosed |
| US-7235549-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7214677-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-20060058302-A1 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. | 2006-03-16 | — | — | US | disclosed |
| EP-1448535-A1 | BENZAMIDE AND HETEROARYLAMIDE AS P2X7 RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-6689771-B2 | TREATMENT OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTITIS, GINGIVITIS, CORNEAL ULCERATION, SOLID TUMOR GROWTH | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-02-10 | — | — | US | disclosed |
| EP-1377589-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-01-07 | — | — | EP | disclosed |
| US-20030186981-A1 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003042191-A1 | BENZAMIDE AND HETEROARYLAMIDE AS P2X7 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-05-22 | — | — | WO | disclosed |
| US-20030032803-A1 | Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase | DUAN JINGWU (US) | 2003-02-13 | — | — | US | disclosed |
| WO-2002062804-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2002-08-15 | — | — | WO | disclosed |
| US-6376665-B1 | ANTIARTHRITIC AGENTS, ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-23 | — | — | US | disclosed |
| EP-1165500-A1 | AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES,TNF-ALPHA,AND AGGRECANASE | Du Pont Pharmaceuticals Company (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059874-A1 | NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186981-A1 | Benzamide, heteroarylamide and reverse amides | P2RX7, P2RX5, P2RX2 | HTR1A 465/4885DRD2 4400/4885CFD 4726/4885 |
| US-20090247734-A1 | Chemically Derivatized CD4 and Uses Thereof | CD4, CD40LG, CD14 | HTR1A 3485/4885DRD2 3078/4885CFD 526/4885 |
| US-20060058302-A1 | Benzamide, heteroarylamide and reverse amides | P2RX7, P2RX5, P2RX2 | HTR1A 452/4885DRD2 3386/4885CFD 4596/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | HTR1A 2279/4885DRD2 1398/4885CFD 3834/4885 |
| US-20030032803-A1 | Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase | TNF, MMP1, ADAMTS1 | HTR1A 4182/4885DRD2 4781/4885CFD 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.